Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00131677 · ClinicalTrials.gov registry record · Phase 2
Extended Safety Study of Tenofovir Disoproxil Fumarate (TDF) Among HIV-1 Negative Men
A Phase 2 study, sponsored by Centers for Disease Control and Prevention.
- Completed
- Registry status
- Phase 2
- Development phase
- 400
- Enrollment target
NCT00131677 is a Phase 2 study that has completed, run by Centers for Disease Control and Prevention. The registered enrollment target is 400 participants.
The verdict
NCT00131677, a Phase 2 study, has completed, sponsored by Centers for Disease Control and Prevention.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 400 participants
- Enrollment target
Study Summary
The purpose of this study is to examine safety and tolerability of daily tenofovir use in HIV-uninfected men.
Interventions
- DRUG placebo
- DRUG tenofovir disoproxil fumarate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2005-02 |
| Est. Completion | 2009-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00131677
The ClinicalTrials.gov registry entry for NCT00131677 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Centers for Disease Control and Prevention, which has 139 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00131677 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00131677 about?
NCT00131677 is a clinical study titled "Extended Safety Study of Tenofovir Disoproxil Fumarate (TDF) Among HIV-1 Negative Men". The purpose of this study is to examine safety and tolerability of daily tenofovir use in HIV-uninfected men.
What is the current status of trial NCT00131677?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 400 participants. The study started on 2005-02. Estimated completion is 2009-08.
What interventions are being tested in trial NCT00131677?
The interventions under investigation include: placebo (DRUG), tenofovir disoproxil fumarate (DRUG).
Who is sponsoring clinical trial NCT00131677?
This trial is sponsored by Centers for Disease Control and Prevention, which has 139 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.